Literature DB >> 391116

Prolonged herpes-zoster infection associated with immunosuppressive therapy.

J G Gallagher, T C Merigan.   

Abstract

Unusually prolonged zoster was observed in four patients, two with cardiac transplants, one with acute lymphocytic leukemia, and one with diffuse histiocytic lymphoma. Lesions increased in number and persisted for 5 to 24 weeks before beginning to resolve. Specific cellular-immune responsiveness to varicella-zoster virus was markedly depressed during these infections. Absolute numbers of T lymphocytes were also very low. Reducing immunosuppressive therapy to increase immune responses appeared to initiate resolution of zoster lesions and halt dissemination. In one patient treatment with adenine arabinoside was also needed for resolution of disseminated zoster. This syndrome appears to be counterpart of the prolonged mucocutaneous herpes-simplex infection previously reported in immunosuppressed cardiac and renal transplant patients.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 391116     DOI: 10.7326/0003-4819-91-6-842

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  11 in total

1.  Preventing infection in neutropenic cancer patients.

Authors:  S M Beutler; N M Barth; A S Bayer
Journal:  West J Med       Date:  1983-05

2.  Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma.

Authors:  A M Arvin; R B Pollard; L E Rasmussen; T C Merigan
Journal:  J Clin Invest       Date:  1980-04       Impact factor: 14.808

Review 3.  Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia.

Authors:  D Gilden
Journal:  J Intern Med       Date:  2011-02-23       Impact factor: 8.989

4.  Clinical and molecular aspects of varicella zoster virus infection.

Authors:  Don Gilden; Maria A Nagel; Ravi Mahalingam; Niklaus H Mueller; Elizabeth A Brazeau; Subbiah Pugazhenthi; Randall J Cohrs
Journal:  Future Neurol       Date:  2009-01-01

5.  Short-course human leukocyte interferon in treatment of herpes zoster in patients with cancer.

Authors:  T C Merigan; J G Gallagher; R B Pollard; A M Arvin
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

6.  Acyclovir resistant varicella zoster and HIV infection.

Authors:  E G Lyall; M M Ogilvie; N M Smith; S Burns
Journal:  Arch Dis Child       Date:  1994-02       Impact factor: 3.791

Review 7.  Recognition and treatment of shingles.

Authors:  A F Nikkels; G E Piérard
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

8.  Herpes Zoster Infections in SLE in a University Hospital in Saudi Arabia: Risk Factors and Outcomes.

Authors:  Afsar Sayeeda; Hussain Al Arfaj; Najma Khalil; A S Al Arfaj
Journal:  Autoimmune Dis       Date:  2010-09-13

Review 9.  Chemotherapy-induced immunosuppression.

Authors:  L Rasmussen; A Arvin
Journal:  Environ Health Perspect       Date:  1982-02       Impact factor: 9.031

10.  IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies.

Authors:  G N Malavige; L T Rohanachandra; L Jones; L Crack; M Perera; N Fernando; D Guruge; G S Ogg
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.